FDA moves to fast-track review of three psychedelic drug studies
Summary
The Food and Drug Administration (FDA) has given faster review status to three companies testing psychedelic drugs for depression and PTSD. This move is part of efforts under President Donald Trump’s administration to possibly approve these treatments.Key Facts
- The FDA granted fast-track review to three companies working on psychedelic therapies.
- Two companies are studying psilocybin, a psychedelic compound, for different types of depression.
- One company is focusing on treatment-resistant depression (TRD).
- Another company is working on major depressive disorder treatment.
- The third company is researching psychedelics for post-traumatic stress disorder (PTSD).
- Fast-track review helps speed up the drug approval process.
- The FDA did not reveal the names of the companies involved.
- This step is part of the current administration’s actions toward new mental health treatments.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.